Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMACMLO)

• Drug Name: LYSERGIC ACID DIETHYLAMIDE Drug Info
• Synonyms: Lysergide; D-Lysergic acid diethylamide; Delysid; D-Lsd; N,N-Diethyllysergamide; Lysergamid; 50-37-3; Lysergsaeurediaethylamid; Cubes; Pearly gates; Heavenly Blue; Lysergaure diethylamid; Royal blue; N,N-Diethyl-D-lysergamide; LSD (alkaloid); Lysergidum; Wedding bells; Lysergsauerediaethylamid; Lysergic acid diethylamide-25; LSD 25; Lysergidum [INN-Latin]; LSD-25; Lisergide [DCIT]; Lysergamide, N,N-diethyl-; Ubergluben; Clearlight; Sunshine; Cupcakes; Greenies; Barrels; Yellows; Trippers; Microdots; Spoonies

Indication

Disease Entry	ICD 11	Status	REF
Addictive disorder	6C50-6C5Z	Withdrawn from market	[1]

• Cross-matching ID:
  PubChem CID: 5761
  ChEBI ID: CHEBI:6605
  CAS Number: CAS 50-37-3
  TTD Drug ID: DMACMLO

Molecule-Related Drug Atlas

Drug(s) Targeting 5-HT 2A receptor (HTR2A)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Metergolin	DMJFP6G	Hyperprolactinaemia	5A60.1	Approved	[6]
ZOTEPINE	DMF3VXA	Anxiety disorder	6B00-6B0Z	Approved	[7]
Iloperidone	DM6AUFY	Schizophrenia	6A20	Approved	[8]
Flibanserin	DM70DTN	Depression	6A70-6A7Z	Approved	[9]
Lurasidone hydrochloride	DMCVPXO	Schizophrenia	6A20	Approved	[10]
Aniracetam	DMOIFW0	Cerebrovascular ischaemia	8B1Z	Approved	[11]
lumateperone tosylate	DMQ8HOJ	Schizophrenia	6A20	Approved	[12]
Sarpogrelate	DMGLP6S	Diabetic complication	5A2Y	Approved	[13]
Pimavanserin	DMR7IVC	Parkinson disease	8A00.0	Approved	[14]
Zicronapine	DMP8ESD	Schizophrenia	6A20	Phase 3	[15]

Drug(s) Targeting 5-HT 1A receptor (HTR1A)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Trazodone	DMK1GBJ	Depression	6A70-6A7Z	Approved	[16]
Buspirone	DMBS632	Anxiety disorder	6B00-6B0Z	Approved	[17]
OPC-34712	DMHG57U	Major depressive disorder	6A70.3	Approved	[18]
Vilazodone	DM4LECQ	Major depressive disorder	6A70.3	Approved	[19]
Flibanserin	DM70DTN	Depression	6A70-6A7Z	Approved	[9]
Gepirone	DMGX5Q0	Major depressive disorder	6A70.3	Approved	[20]
TERTATOLOL	DM2L3D5	Hypertension	BA00-BA04	Approved	[21]
Urapidil	DMD59GI	Hypertension	BA00-BA04	Approved	[22]
Treximet	DMU54QB	Migraine	8A80	Approved	[23]
CM-2395	DMASPWR	Schizophrenia	6A20	Phase 3	[24]

Drug(s) Affected By 5-hydroxytryptamine receptor 2B (HTR2B)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Gabapentin	DM6T924	Complex partial seizure	8A68.0	Approved	[25]
Marinol	DM70IK5	Anorexia nervosa cachexia	6B80	Approved	[26]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[27]
Mifepristone	DMGZQEF	Cushing disease	5A70	Approved	[28]
Dasatinib	DMJV2EK	Blast phase chronic myelogenous leukemia, BCR-ABL1 positive		Approved	[29]
Bortezomib	DMNO38U	Leukemia		Approved	[30]
Estradiol	DMUNTE3	Acne vulgaris	ED80	Approved	[31]
Progesterone	DMUY35B	Amenorrhea	GA20.0	Approved	[32]
Fenfluramine	DM0762O	Dravet syndrome	8A61.11	Phase 3	[33]
GSK2110183	DMZHB37	leukaemia	2A60-2B33	Phase 2	[34]

Drug(s) Affected By 5-hydroxytryptamine receptor 6 (HTR6)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Clozapine	DMFC71L	Schizophrenia	6A20	Approved	[35]
Olanzapine	DMPFN6Y	Bipolar depression		Approved	[35]
Methamphetamine	DMPM4SK	Anxiety		Approved	[36]
Benzo(a)pyrene	DMN7J43	N. A.	N. A.	Phase 1	[37]
SB 258585	DM2QJKZ	Discovery agent	N.A.	Investigative	[38]
Formaldehyde	DM7Q6M0	Discovery agent	N.A.	Investigative	[39]

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
5-HT 1A receptor (HTR1A)	TTSQIFT	5HT1A_HUMAN	Inhibitor	[2]
5-HT 2A receptor (HTR2A)	TTJQOD7	5HT2A_HUMAN	Inhibitor	[3]

Drug Off-Target (DOT)

DOT Name	DOT ID	UniProt ID	Interaction	REF
5-hydroxytryptamine receptor 2B (HTR2B)	OTM1AD9J	5HT2B_HUMAN	Protein Interaction/Cellular Processes	[4]
5-hydroxytryptamine receptor 6 (HTR6)	OT8GTDDY	5HT6R_HUMAN	Protein Interaction/Cellular Processes	[5]

References

• [1] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 17).
• [2] Stereoselective LSD-like activity in a series of d-lysergic acid amides of (R)- and (S)-2-aminoalkanes. J Med Chem. 1995 Mar 17;38(6):958-66.
• [3] C-(4,5,6-trimethoxyindan-1-yl)methanamine: a mescaline analogue designed using a homology model of the 5-HT2A receptor. J Med Chem. 2006 Jul 13;49(14):4269-74.
• [4] Pharmacokinetic and pharmacodynamic evaluation of 5-methoxy-2-aminoindane (MEAI): A new binge-mitigating agent. Toxicol Appl Pharmacol. 2018 Mar 15;343:29-39. doi: 10.1016/j.taap.2018.02.009. Epub 2018 Feb 16.
• [5] N'-(arylsulfonyl)pyrazoline-1-carboxamidines as novel, neutral 5-hydroxytryptamine 6 receptor (5-HT?R) antagonists with unique structural features. J Med Chem. 2011 Oct 27;54(20):7030-54. doi: 10.1021/jm200466r. Epub 2011 Sep 26.
• [6] Pharmacological characterisation of the agonist radioligand binding site of 5-HT(2A), 5-HT(2B) and 5-HT(2C) receptors. Naunyn Schmiedebergs Arch Pharmacol. 2004 Aug;370(2):114-23.
• [7] Current and novel approaches to the drug treatment of schizophrenia. J Med Chem. 2001 Feb 15;44(4):477-501.
• [8] Hughes B: 2009 FDA drug approvals. Nat Rev Drug Discov. 2010 Feb;9(2):89-92.
• [9] Radium 223 dichloride for prostate cancer treatment. Drug Des Devel Ther. 2017 Sep 6;11:2643-2651.
• [10] Mullard A: 2010 FDA drug approvals. Nat Rev Drug Discov. 2011 Feb;10(2):82-5.
• [11] Anxiolytic effects of aniracetam in three different mouse models of anxiety and the underlying mechanism. Eur J Pharmacol. 2001 May 18;420(1):33-43.
• [12] Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health Human Services. 2019
• [13] Beneficial effects of sarpogrelate hydrochloride, a 5-HT2A receptor antagonist, supplemented with pioglitazone on diabetic model mice. Endocr Res. 2009;34(1-2):18-30.
• [14] Pimavanserin, a selective serotonin (5-HT)2A-inverse agonist, enhances the efficacy and safety of risperidone, 2mg/day, but does not enhance efficacy of haloperidol, 2mg/day: comparison with reference dose risperidone, 6mg/day.Schizophr Res.2012 Nov;141(2-3):144-52.
• [15] Clinical pipeline report, company report or official report of Lundbeck.
• [16] Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
• [17] Interactions between corticotropin-releasing hormone and serotonin: implications for the aetiology and treatment of anxiety disorders. Handb Exp Pharmacol. 2005;(169):181-204.
• [18] Effects of brexpiprazole, a novel serotonin-dopamine activity modulator, on phencyclidine-induced cognitive deficits in mice: a role for serotonin 5-HT1A receptors.Pharmacol Biochem Behav.2014 Sep;124:245-9.
• [19] 2011 FDA drug approvals. Nat Rev Drug Discov. 2012 Feb 1;11(2):91-4.
• [20] Novel drugs and therapeutic targets for severe mood disorders. Neuropsychopharmacology. 2008 Aug;33(9):2080-92.
• [21] Synthesis of new derivatives of 8-OH-DPAT: Influence of substitution on the aromatic ring on the pharmacological profile, Bioorg. Med. Chem. Lett. 3(10):2035-2038 (1993).
• [22] Urapidil. A reappraisal of its use in the management of hypertension. Drugs. 1998 Nov;56(5):929-55.
• [23] Clinical pipeline report, company report or official report of GlaxoSmithKline (2009).
• [24] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800031127)
• [25] ADReCS-Target: target profiles for aiding drug safety research and application. Nucleic Acids Res. 2018 Jan 4;46(D1):D911-D917. doi: 10.1093/nar/gkx899.
• [26] Evaluation of first generation synthetic cannabinoids on binding at non-cannabinoid receptors and in a battery of in?vivo assays in mice. Neuropharmacology. 2016 Nov;110(Pt A):143-153. doi: 10.1016/j.neuropharm.2016.07.016. Epub 2016 Jul 20.
• [27] Integrative omics data analyses of repeated dose toxicity of valproic acid in vitro reveal new mechanisms of steatosis induction. Toxicology. 2018 Jan 15;393:160-170.
• [28] Mifepristone induced progesterone withdrawal reveals novel regulatory pathways in human endometrium. Mol Hum Reprod. 2007 Sep;13(9):641-54.
• [29] Dasatinib reverses cancer-associated fibroblasts (CAFs) from primary lung carcinomas to a phenotype comparable to that of normal fibroblasts. Mol Cancer. 2010 Jun 27;9:168.
• [30] The proapoptotic effect of zoledronic acid is independent of either the bone microenvironment or the intrinsic resistance to bortezomib of myeloma cells and is enhanced by the combination with arsenic trioxide. Exp Hematol. 2011 Jan;39(1):55-65.
• [31] 17-Estradiol Activates HSF1 via MAPK Signaling in ER-Positive Breast Cancer Cells. Cancers (Basel). 2019 Oct 11;11(10):1533. doi: 10.3390/cancers11101533.
• [32] Effects of progesterone treatment on expression of genes involved in uterine quiescence. Reprod Sci. 2011 Aug;18(8):781-97.
• [33] Serotonin 5-HT(2B) receptor loss of function mutation in a patient with fenfluramine-associated primary pulmonary hypertension. Cardiovasc Res. 2003 Dec 1;60(3):518-28. doi: 10.1016/j.cardiores.2003.09.015.
• [34] Novel ATP-competitive Akt inhibitor afuresertib suppresses the proliferation of malignant pleural mesothelioma cells. Cancer Med. 2017 Nov;6(11):2646-2659. doi: 10.1002/cam4.1179. Epub 2017 Sep 27.
• [35] No evidence for binding of clozapine, olanzapine and/or haloperidol to selected receptors involved in body weight regulation. Pharmacogenomics J. 2007 Aug;7(4):275-81. doi: 10.1038/sj.tpj.6500418. Epub 2006 Sep 19.
• [36] Serotonin 6 receptor gene is associated with methamphetamine-induced psychosis in a Japanese population. Drug Alcohol Depend. 2011 Jan 1;113(1):1-7. doi: 10.1016/j.drugalcdep.2010.06.021. Epub 2010 Aug 11.
• [37] Air pollution and DNA methylation alterations in lung cancer: A systematic and comparative study. Oncotarget. 2017 Jan 3;8(1):1369-1391. doi: 10.18632/oncotarget.13622.
• [38] 5-HT6 receptor binding sites in schizophrenia and following antipsychotic drug administration: autoradiographic studies with [125I]SB-258585. Synapse. 2002 Sep 1;45(3):191-9.
• [39] Characterization of formaldehyde's genotoxic mode of action by gene expression analysis in TK6 cells. Arch Toxicol. 2013 Nov;87(11):1999-2012.